SCHEMBL15670352

SCHEMBL15670352

COc1cnc([N+](=O)[O-])c(O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.39
LMNA P02545 4/20 0.39
HTT P42858 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 4/20 0.39
MAPK1 P28482 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPSR1 Q6W5P4 3/20 0.39
MEN1 O00255 3/20 0.39
CYP3A4 P08684 2/20 0.38
NPC1 O15118 6/20 0.38
RAB9A P51151 4/20 0.38
S1PR4 O95977 1/20 0.36
TPMT P51580 1/20 0.36
HSP90AA1 P07900 1/20 0.36
PKM P14618 1/20 0.36
PAX8 Q06710 1/20 0.36
ALDH1A1 P00352 2/20 0.36
GALR2 O43603 1/20 0.36
EGFR P00533 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30032133 0.81 ALDH1A1 (0.41) MAPTLMNAHTTKMT2ASMN1; SMN2
SCHEMBL28279919 0.80 MAPT (0.35) MAPTLMNAHTTL3MBTL1KMT2A
SCHEMBL9622184 0.80 MAPT (0.36) MAPTLMNAHTTL3MBTL1KMT2A
SCHEMBL16564138 0.79 MAPT (0.44) MAPTLMNAHTTKMT2AMAPK1
SCHEMBL15390819 0.79 AMY1A (0.38) MAPTLMNAKMT2AMAPK1SMN1; SMN2
SCHEMBL7494690 0.77 SMN1; SMN2 (0.42) MAPTLMNAHTTKMT2AMAPK1
SCHEMBL9321402 0.76 MAPT (0.44) MAPTLMNAHTTKMT2AMAPK1
SCHEMBL15608667 0.76 MAPK1 (0.48) MAPTLMNAL3MBTL1KMT2AMAPK1
SCHEMBL8566803 0.74 ALOX15 (0.44) MAPTLMNAHTTL3MBTL1KMT2A
SCHEMBL27313759 0.73 NPC1 (0.36) MAPTHTTKMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024038357-A1 SYNTHESIS OF SUBSTITUTED TETRACYCLIC CARBOXYLIC ACIDS AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORPORATION (CA) 2024-02-22 WO claimed
US-20250179045-A1 LPAR1 ANTAGONISTS AND USES THEREOF CONTINEUM THERAPEUTICS, INC. 2025-06-05 US disclosed
US-20250034110-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. 2025-01-30 US disclosed
EP-4380560-A1 LPAR1 ANTAGONISTS AND USES THEREOF Contineum Therapeutics, Inc. (US) 2024-06-12 EP disclosed
CN-118043041-A LPAR1 antagonists and uses thereof 康蒂内乌姆医疗公司 2024-05-14 CN disclosed
WO-2024038357-A1 SYNTHESIS OF SUBSTITUTED TETRACYCLIC CARBOXYLIC ACIDS AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORPORATION (CA) 2024-02-22 WO disclosed
WO-2024038357-A1 SYNTHESIS OF SUBSTITUTED TETRACYCLIC CARBOXYLIC ACIDS AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORPORATION (CA) 2024-02-22 WO disclosed
WO-2023014907-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. (US) 2023-02-09 WO disclosed
WO-2023014908-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. (US) 2023-02-09 WO disclosed
WO-2022214937-A1 SUBSTITUTED TETRACYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2022-10-13 WO disclosed
EP-3119778-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE Bayer Pharma Aktiengesellschaft (DE) 2017-01-25 EP disclosed
US-20150274719-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-10-01 US disclosed
US-20150274719-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-10-01 US disclosed
WO-2015140254-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-09-24 WO disclosed
WO-2015140199-A1 CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-09-24 WO disclosed
WO-2015140199-A1 CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-09-24 WO disclosed
WO-2015140254-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-09-24 WO disclosed
EP-2914594-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE Bayer Pharma Aktiengesellschaft (DE) 2015-09-09 EP disclosed
US-20140179672-A1 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-06-26 US disclosed
WO-2014068099-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179045-A1 LPAR1 ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR3 MAPT 4647/4885LMNA 1243/4885HTT 3737/4885
US-20140179672-A1 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use AADAC, TNNI3, PAICS MAPT 4608/4885LMNA 252/4885HTT 4068/4885
US-20250034110-A1 LPAR1 ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR3 MAPT 4647/4885LMNA 1243/4885HTT 3737/4885
US-20150274719-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AADAC, TNNI3, PAICS MAPT 4608/4885LMNA 252/4885HTT 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.